TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01070056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (MINT-TLC)
Description: This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
Study: NCT04086758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a 2-hour intravenous infusion
Study: NCT03484234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultimaster stent
Description: Percutaneous coronary intervention with Ultimaster stent for long lesion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience alpine stent
Description: Percutaneous coronary intervention with Xience alpine stent for long lesion
Study: NCT00610506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
Study: NCT03996837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra uterine infusion of platelet rich plasma
Description: Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra uterine infusion of platelet rich plasma
Description: Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
Study: NCT01673841

Intervention type: PROCEDURE
Intervention: Relative and absolute cerebral oxygen saturation (rScO2) measurements.
Study: NCT04334850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin
Description: The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual antibiotic treatment
Description: The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
Study: NCT04212819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Before Erythrocyte Suspension (ES)
Description: ES transfusion needs of the patients were determined according to clinical signs and symptoms. Vital signs were closely monitored and recorded before, during and after transfusion. Infusion was performed slowly for the first 15 minutes in terms of allergic reaction, and then the transfusion rate was adjusted according to the patient's clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: After Erythrocyte Suspension (ES)
Description: Venous blood samples were obtained from patients who needed ES transfusion before transfusion. Control venous blood samples were obtained from the patients who did not develop any complications for 24 hours after starting of the transfusion and became hemodynamically stable.
Study: NCT03927495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: palliative radiotherapy
Description: 3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
Study: NCT04487522

Intervention type: PROCEDURE
Intervention: Open retromuscular ventral hernia repair
Description: With the subject under general anesthesia, a single incision is made in the abdomen. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.

Intervention type: PROCEDURE
Intervention: Open retromuscular ventral hernia repair
Description: With the subject under general anesthesia, a single incision is made in the abdomen. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.

Intervention type: PROCEDURE
Intervention: Laparoscopic retromuscular ventral hernia repair
Description: With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.

Intervention type: DEVICE
Intervention: Robotic-assisted retromuscular ventral hernia repair
Description: With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.

Intervention type: DEVICE
Intervention: Robotic-assisted retromuscular ventral hernia repair
Description: With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
Study: NCT03646643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Atrial fibrillation ablation
Description: The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Atrial fibrillation ablation
Description: The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary sinus to left atrium connection elimination
Description: Distal coronary sinus pacing will be utilized to localize distal connections between the main coronary sinus body and the left atrium. Focal lesions will be applied to early left atrial activation sites, until no distal coronary sinus to left atrial connections are electrically manifest. If vein of marshall connections to the left atrium are present, differential pacing will be utilized to prove the lack of distal coronary sinus to left atrium connections.
Study: NCT03489551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haldol
Study: NCT01389518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: 1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
Study: NCT03900949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic SCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study: NCT03992430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Description: Solution for intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Description: Solution for intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Description: Solution for intravenous (IV) infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eteplirsen
Description: Solution for intravenous (IV) infusion.
Study: NCT03900949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO
Study: NCT04251806

Intervention type: DIAGNOSTIC_TEST
Intervention: neonatal polysomnography
Description: This procedure will allow the detection of sleep-disordered breathing in the neonatal period.

Intervention type: DIAGNOSTIC_TEST
Intervention: neonatal polysomnography
Description: This procedure will allow the detection of sleep-disordered breathing in the neonatal period.

Intervention type: DIAGNOSTIC_TEST
Intervention: 2-year Bayley Exam
Description: This procedure will evaluate neurodevelopmental outcomes.

Intervention type: DIAGNOSTIC_TEST
Intervention: 2-year Bayley Exam
Description: This procedure will evaluate neurodevelopmental outcomes.

Intervention type: DIAGNOSTIC_TEST
Intervention: 2-year polysomnography
Description: This procedure will allow the detection of sleep-disordered breathing at 2 years of age.

Intervention type: DIAGNOSTIC_TEST
Intervention: 2-year polysomnography
Description: This procedure will allow the detection of sleep-disordered breathing at 2 years of age.
Study: NCT03874598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Description: Patients in the intervention group are treated twice a week for five weeks using semi-standardized ear acupuncture.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Patients of the control group receive a 1,5 h psychoeducation group concerning sleep improving behaviour.
Study: NCT00763204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Cream, 2%
Study: NCT02232191

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax-23

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax-23

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax-23
Study: NCT03315754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD Soluble 4 mg/kg
Description: Vascular targeted photodynamic therapy using TOOKAD Soluble
Study: NCT02415621

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone Acetate
Description: 1000 mg by mouth (PO) every day (QD)
Study: NCT01587352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT03553836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an IV infusion every 3 weeks (Q3W)
Study: NCT03930953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat
Description: Specified dose on specified days
Study: NCT03834493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Capsules/Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enzalutamide
Description: Capsules/Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT06698198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine
Description: Suspension for Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine
Description: Suspension for Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine
Description: Suspension for Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine
Description: Suspension for Intramuscular injection
Study: NCT03976245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tofacitinib
Description: tablet
Study: NCT03469570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature
Description: Subjects enrolled in the validation study will have their fluid management decisions guided by the AFM Feature.
Study: NCT02986516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized Cohort
Description: Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prospective cohort
Description: Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated
Study: NCT04029688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.
Study: NCT06698198

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Suspension for Intramuscular injection
Study: NCT02402920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04339166

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive chromosome screening（NICS）
Description: NICS is noninvasive chromosome screening approach to analysis the euploidy by free DNA in embryo culture medium
Study: NCT03778957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab IV (intravenous)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
Study: NCT00748527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study: NCT04525469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: NET involves: 1) diagnostic interview and psychoeducation, 2) laying out the Lifeline, 3) NET therapy sessions (constructing the trauma narrative in context of the life course), 4) final session rituals. Laying out the Lifeline (using rope or string) allows participants to take a bird's eye view of the events of their life using simple items such as flowers to represent positive events and stones to represent traumatic events. The focus of NET sessions is to encourage participants to describe the details of traumas and integrating the cold memories (i.e., facts) with the hot memories (e.g., cognitions, emotions, physiological feelings, and sensory information). The therapist makes notes after each session narrating the details of the traumas (stones) and reads this at the beginning of each subsequent session. Final session rituals involve re-reading the trauma narrative, hopes for the future, and laying out the final Lifeline placing flowers for hopes and wishes for the future.
Study: NCT03778957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE (chemo and embolic agent injection into the hepatic artery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE (chemo and embolic agent injection into the hepatic artery)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE (chemo and embolic agent injection into the hepatic artery)